Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amneal Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Amneal Pharmaceuticals, Inc.’s stock price such as:

• Amneal Pharmaceuticals, Inc.’s current stock price and volume
• Why Amneal Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for AMRX from analysts
• AMRX’s stock price momentum as measured by its relative strength

About Amneal Pharmaceuticals, Inc. (AMRX)

Before we jump into Amneal Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson’s disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Want to learn more about Amneal Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, Amneal Pharmaceuticals, Inc.’s stock price was $13.585.

Amneal Pharmaceuticals, Inc. is down 0.98% from its previous closing price of $13.720.

During the last market session, Amneal Pharmaceuticals, Inc.’s stock traded between $13.484 and $13.810. Currently, there are approximately 314.46 million shares outstanding for Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 62.4, which is high compared to the Pharmaceuticals industry median of 19.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Amneal Pharmaceuticals, Inc. Stock Price History

Amneal Pharmaceuticals, Inc.’s (AMRX) price is currently up 5.56% so far this month.

During the month of May, Amneal Pharmaceuticals, Inc.’s stock price has reached a high of $13.840 and a low of $12.375.

Over the last year, Amneal Pharmaceuticals, Inc. has hit prices as high as $15.420 and as low as $7.020. Year to date, Amneal Pharmaceuticals, Inc.’s stock is up 7.82%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Amneal Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded Amneal Pharmaceuticals, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Amneal Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amneal Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amneal Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amneal Pharmaceuticals, Inc. (AMRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Amneal Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Amneal Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 6.81%, which translates to a Momentum Score of 75 and is considered to be Strong.

Want to learn more about how Amneal Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amneal Pharmaceuticals, Inc. Stock Price: Bottom Line

As of May 8, 2026, Amneal Pharmaceuticals, Inc.’s stock price is $13.585, which is down 0.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amneal Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.